A 2020 paper found that sodium-glucose cotransporter-2 (SGLT-2) antagonist Empagliflozin reduced vascular damage and cognitive impairment in AD-T2D mice showing potential for treatment [95]. Here, SLC5A2 is linked to Alzheimer disease.